Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 14/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327553 | 0.88 | CTSA (0.41) | CTSA | |
| SCHEMBL4338765 | 0.88 | FFAR2 (0.36) | CTSAKDM4EALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL4320658 | 0.86 | MEN1 (0.40) | CTSAALDH1A1SMN1; SMN2KMT2AHTT | |
| SCHEMBL4336867 | 0.79 | TSHR (0.38) | CTSA | |
| SCHEMBL4335154 | 0.76 | TDP1 (0.40) | CTSAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL28475689 | 0.75 | FAAH (0.38) | CTSA | |
| SCHEMBL4322239 | 0.75 | CTSA (0.37) | CTSAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6607172 | 0.73 | FAAH (0.42) | CTSAALOX5 | |
| SCHEMBL1827574 | 0.72 | FAAH (0.36) | CTSA | |
| SCHEMBL4334425 | 0.69 | CTSA (0.38) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | CTSA 1028/4885KDM4E 1921/4885ALDH1A1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.